Infertility is a global health issue affecting women and men of reproductive age with increasing incidence worldwide, in part due to greater awareness and better diagnosis. Assisted reproduction technologies (ART) are considered the ultimate step in the treatment of infertility. Recently, artificial intelligence (AI) has been progressively used in the many fields of medicine, integrating knowledge and computer science through machine learning algorithms. AI has the potential to improve infertility diagnosis and ART outcomes estimated as pregnancy and/or live birth rate, especially with recurrent ART failure. A broad-ranging review has been conducted, focusing on clinical AI applications up until September 2022, which could be estimated in terms of possible applications, such as ultrasound monitoring of folliculogenesis, endometrial receptivity, embryo selection based on quality and viability, and prediction of post implantation embryo development, in order to eliminate potential contributing risk factors. Oocyte morphology assessment is highly relevant in terms of successful fertilization rate, as well as during oocyte freezing for fertility preservation, and substantially valuable in oocyte donation cycles. AI has great implications in the assessment of male infertility, with computerised semen analysis systems already in use and a broad spectrum of possible AI-based applications in environmental and lifestyle evaluation to predict semen quality. In addition, considerable progress has been made in terms of harnessing AI in cases of idiopathic infertility, to improve the stratification of infertile/fertile couples based on their biological and clinical signatures. With AI as a very powerful tool of the future, our review is meant to summarise current AI applications and investigations in contemporary reproduction medicine, mainly focusing on the nonsurgical aspects of it; in addition, the authors have briefly explored the frames of reference and guiding principles for the definition and implementation of legal, regulatory, and ethical standards for AI in healthcare.

Hyperandrogenism is a condition in which the levels of androgen hormones in the blood are significantly increased and could be of an adrenal or ovarian origin. The adrenal androgens, normally secreted by the zona reticularis, are steroid hormones with weak androgen activity. The causes of hyperandrogenism are diverse and could be endogenous and exogenous. Androgen excess affecting different tissues and organs results in clinical features such as acne, hirsutism, virilization, and reproductive dysfunction such as oligomenorrhoea/amenorrhoea. Although androgen excess is rarely associated with adrenal tumours, it is important as it could be predictive of malignancy. A careful evaluation of the androgen pattern, also in patients with clear signs of hyperandrogenism, could be useful. Laboratory evaluation should focus on measuring total testosterone levels, followed by the estimation of other androgens such as dehydroepiandrosterone and androstenedione, and using visualisation procedures in the further management. The treatment of adrenal hyperandrogenism is eminently surgical, in consideration of the frequent malignant origin. The aim of this review is to elaborate and summarize the prevalence and clinical management of hyperandrogenism of an adrenal origin by describing the physiological mechanisms of adrenal androgen steroidogenesis, the clinical manifestations of hyperandrogenism with a special reference to hyperandrogenism in adrenal adenomas and carcinomas, and the diagnostic methods that will lead us to establishing the correct diagnosis and different treatment options to manage this condition according to the clinical presentation of the patient.

Background: Papillary thyroid carcinoma (PTC) arising within an ovarian teratoma is an extremely rare condition that comes with certain difficulties in the preoperative diagnosis and postoperative treatment strategy. It is either asymptomatic (detected incidentally) or with nonspecific symptoms. Currently, no consensus exists on the surgical and postoperative treatment of patients with malignant struma ovarii. Case presentation: A 26-year-old female presented with dizziness, reoccurring epistaxis and a palpable mass on her right breast, diagnosed by mammography as fibroadenoma. Preoperative pelvic ultrasonography revealed a presence of a 9 cm right ovarian tumor and free fluid filling the pouch of Douglas. She had elevated Ca19-9 levels of 88 IU/ml and normal Ca-125 levels (25.7 IU/ml). The patient underwent a laparoscopic ovarian cystectomy along with fibroadenomectomy. Pathohistological evaluation of the operative material declared as a dermoid cyst confirmed a diagnosis of PTC measuring 2.4 cm in the ovarian teratoma. She was admitted to the Institute of Pathophisiology and Nuclear Medicine for further investigation and management. Her thyroid examinations showed euthyroid condition with normal thyroid and neck morphology on ultrasound and normal thyroglobulin (Tg) levels. The PET – CT scan showed no sites of metastatic spread. The patient was informed about the treatment approaches and was given suppressive doses of Levothyroxine (TSH 0.004 mIU/l were achieved with 150 μg/day) until her final decision. Conclusions: The management of malignant struma ovarii is based on rare case-report studies. The therapy ranges from radical surgery and radio-chemotherapy, thyroidectomy, radioiodine ablation and levothyroxine TSH suppression, to conservative surgery in younger patients with fertility preservation. Early diagnosis based on modern imaging techniques impacts the clinical decision and management, which produces a better outcome regarding the future prognosis.